Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Enterprise Value: 2022-2025

Historic Enterprise Value for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $127.3 million.

  • Entrada Therapeutics' Enterprise Value fell 79.42% to $127.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.2 million, marking a year-over-year decrease of 138.40%. This contributed to the annual value of $545.8 million for FY2024, which is 25.20% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Enterprise Value of $127.3 million as of Q3 2025, which was down 30.26% from $182.6 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Enterprise Value high stood at $618.7 million for Q3 2024, and its period low was $29.5 million during Q1 2022.
  • Moreover, its 3-year median value for Enterprise Value was $407.7 million (2024), whereas its average is $359.2 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first surged by 469.87% in 2023, then tumbled by 79.42% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Enterprise Value (Quarterly) stood at $301.5 million in 2022, then soared by 44.59% to $435.9 million in 2023, then grew by 25.20% to $545.8 million in 2024, then slumped by 79.42% to $127.3 million in 2025.
  • Its Enterprise Value stands at $127.3 million for Q3 2025, versus $182.6 million for Q2 2025 and $272.0 million for Q1 2025.